Jeremy Grushcow at The Cross-Border Biotech Blog points to the KRAS mutation genetic test to identify patients who won't respond to Erbitux or Vectibix as "exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and payors." Grushcow says payors benefit by the elimination of unneces